Peptides for Covid-19 prevention and treatment
AssigneeSotira Covid, LLC
InventorsAvik Roy, Carl Gunnar Gottschalk
Life of this patent
Estimating the term…
Abstract
Embodiments include therapeutic peptides for preventing or reducing the transmission of a coronavirus such as SARS-CoV2. Also included are methods of using therapeutic peptides for reducing or preventing transmission of a coronavirus such as SARS-CoV2. The therapeutic peptides can prevent a region of the surface glycoprotein “spike” on SARS-CoV2 from interacting with angiotensin converting enzyme-2 (ACE-2) of host cells.
Claims27
A peptide having at least 70% sequence identity to SEQ ID NO:
- 1, wherein the peptide comprises a carboxy-terminal lysine residue and a biotin residue.
A peptide with amino acid sequence of SEQ ID NO:
- 1 that binds to ACE-2 receptor and prevents formation of a complex with SARS-CoV2.
A method of preventing or treating a coronavirus virus infection in a patient that is susceptible to the virus infection, comprising steps of:
- a) administering a peptide with amino acid sequence of SEQ ID NO:
- 1 to a respiratory system of the patient, and
- b) preventing or attenuating formation of a complex between a viral surface protein and a receptor on a host cell.
A peptide with amino acid sequence of SEQ ID NO:
- 1 that binds to ACE-2 receptor and prevents an interaction between a viral surface protein of coronavirus and the ACE-2 receptor.
Dependencies are inferred from the claim text.